AcroMeta Group Limited (SGX: 43F), a facility management services provider listed on the Catalist board of the Singapore Exchange, has announced a strategic move into the emerging field of ambient temperature cellular logistics (ATCLS). The company has entered into a non-binding term sheet with Macro HRD SG Pte. Ltd., a Singapore-based healthcare consultancy, to acquire a strategic stake in Macro-ATCLS Pte. Ltd., the entity commercializing the ATCLS technology. This partnership includes an option for AcroMeta to obtain an exclusive license to deploy the technology across Southeast Asia, with rights to appoint sub-licensees and a first right to acquire additional territories.
The ATCLS technology, licensed by Macro HRD, aims to transform the transportation of living cells and temperature-sensitive biological materials by eliminating the need for conventional refrigerated and cryogenic cold chains. It uses proprietary ambient-temperature preservation and reactivation methods, supported by the Gradient Equilibrium Decision Modeling (GEDM) platform for real-time governance and process control. This allows dormant cells to be transported at ambient temperatures and reactivated at their destination, potentially reducing costs, fragility, and geographic limitations associated with traditional cold-chain logistics.
The markets addressed by this technology are substantial. According to project materials provided by Macro's management, the global cell-and-gene-therapy third-party logistics market was estimated at US$1.81 billion in 2025 and is projected to reach US$16.95 billion by 2035, a compound annual growth rate of 25.1%. The serviceable addressable market (SAM) for ambient-addressable segments is estimated at approximately US$14.5 billion by 2032. These figures highlight the significant growth potential in cell and gene therapy logistics, which is expected to expand at double-digit rates in the coming years.
Lawrence Toh, Executive Director of AcroMeta Group Limited, commented, "This proposed strategic partnership gives us the opportunity to build a position in an industry where cell and gene therapy logistics are expected to grow at double-digit rates in the years ahead. We see this as a natural extension of our strategy to grow our portfolio beyond our core operations, and we’re excited about the potential to build a meaningful presence in bringing this technology into Southeast Asia."
The Group intends to continue evaluating strategic opportunities that support its long-term growth, focusing on disciplined capital allocation. The Board believes this partnership aligns with its goal of creating long-term shareholder value. The non-binding term sheet marks the beginning of negotiations, and the final terms will be subject to due diligence and definitive agreements.
This announcement underscores AcroMeta's strategic pivot towards high-growth sectors, leveraging its existing operational expertise to enter a market with transformative potential. The move is expected to diversify the Group's revenue streams and position it as a key player in the regional biotech logistics landscape.
